Correction to: Phase II study of bi-weekly temozolomide plus bevacizumab for adult patients with recurrent glioblastoma (Cancer Chemotherapy and Pharmacology, (2017), 80, 4, (715-721), 10.1007/s00280-017-3405-7)

Michael A. Badruddoja, Marjorie Pazzi, Abhay Sanan, Kurt Schroeder, Kevin Kuzma, Thomas Norton, Thomas Scully, Daruka Mahadevan, Michael Malek Ahmadi

Research output: Contribution to journalComment/debatepeer-review

1 Scopus citations

Abstract

The author would like to correct the errors in the publication of the original article. The corrected details are given below for your reading. The second sentence of the “Introduction” section should read as: A majority of these patients will have glioblastoma, the most malignant variant of glioma [1].

Original languageEnglish (US)
Pages (from-to)223
Number of pages1
JournalCancer chemotherapy and pharmacology
Volume81
Issue number1
DOIs
StatePublished - Jan 1 2018

ASJC Scopus subject areas

  • Oncology
  • Toxicology
  • Pharmacology
  • Cancer Research
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Correction to: Phase II study of bi-weekly temozolomide plus bevacizumab for adult patients with recurrent glioblastoma (Cancer Chemotherapy and Pharmacology, (2017), 80, 4, (715-721), 10.1007/s00280-017-3405-7)'. Together they form a unique fingerprint.

Cite this